Search
Immunocore Holdings PLC
IMCRAdd to Watchlist
32.260USD
+0.610+1.93%
Market hours （ET）Quotes delayed by 15 min
1.64BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.02%
5 Days
+7.67%
1 Month
+10.85%
6 Months
-6.97%
Year to Date
-6.97%
1 Year
-1.67%
Key Figures
31.800Open
32.420High
77.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.15%Turnover Ratio
31.650Prev. Close
31.540Low
1.63MTurnover
LossP/E Static
4.17P/B
0.00%Div Yield TTM
-2.63%ROA
40.71552wk High
0.70Volume Ratio
-51.09MNet Profit
50.87MShares
-0.5501EPS TTM
0.75Beta
-7.14%ROE
27.55552wk Low
2.78%Amplitude
99.59%Gross Margin
1.64BMarket Cap
3.15Reward/Risk
2.25%Risk Rate
TradingKey Stock Score of Immunocore Holdings PLC
Currency: USD Updated: 2026-07-01Key Insights
Immunocore Holdings PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 66.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunocore Holdings PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Immunocore Holdings PLC Highlights
StrengthsRisks
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 60.37% year-on-year.
Fairly Valued
The company’s latest PE is -57.53, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.60M shares, decreasing 16.54% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 66.62K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
66.500
Target Price
+109.45%
Upside Space
Immunocore Holdings PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immunocore Holdings PLC Info
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Ticker SymbolIMCR
CompanyImmunocore Holdings PLC
CEOJallal (Bahija)
Websitehttps://www.immunocore.com/
Related Instruments
+1.98%
+1.46%
+4.04%
+1.53%
+1.92%
+2.98%
+2.21%
+3.70%
+2.11%
+1.84%
+3.62%
+2.58%
+3.25%
+2.65%
+1.45%
0.00%
+2.27%
+3.91%
+0.58%
+4.20%Popular Instruments
52706.900
+452.600 (+0.87%)
29853.400
+54.100 (+0.18%)
7525.700
+50.200 (+0.67%)
14847.000
-508.000 (-3.31%)
69079.000
-406.000 (-0.58%)
6374.400
+99.000 (+1.58%)
67.474
-0.494 (-0.73%)
303.210
+8.830 (+3.00%)
198.800
+1.220 (+0.62%)
4124.570
+93.800 (+2.33%)
FAQs
What is the current price of Immunocore Holdings PLC (IMCR)?
The current price of Immunocore Holdings PLC (IMCR) is 31.65.
What is the symbol of Immunocore Holdings PLC?
The ticker symbol of Immunocore Holdings PLC is IMCR.
What is the 52-week high of Immunocore Holdings PLC?
The 52-week high of Immunocore Holdings PLC is 40.71.
What is the 52-week low of Immunocore Holdings PLC?
The 52-week low of Immunocore Holdings PLC is 27.55.
What is the market capitalization of Immunocore Holdings PLC?
The market capitalization of Immunocore Holdings PLC is 1.61B.
Is Immunocore Holdings PLC (IMCR) currently rated as Buy, Hold, or Sell?
According to analysts, Immunocore Holdings PLC (IMCR) has an overall rating of Buy, with a price target of 66.50.
What is the Earnings Per Share (EPS TTM) of Immunocore Holdings PLC (IMCR)?
The Earnings Per Share (EPS TTM) of Immunocore Holdings PLC (IMCR) is -0.71.